The State of the Global Biotech Market

The Current Landscape of the Global Biotechnology Market

The global biotechnology market has become more critical than ever, propelled by an aging population, the rise of chronic diseases, and the global experience of the COVID-19 pandemic. According to a report by MarketsandMarkets™, the market is projected to grow from approximately $1.5 trillion in 2024 to $3.2 trillion by 2030, registering a Compound Annual Growth Rate (CAGR) of 12.8%.

• Growth Drivers: Market expansion is being driven by advancements in life science technologies such as genomics and proteomics, increased efficiency in new drug development leveraging AI, and a growing demand for personalized, precision medicine.

• Key Segments: High-growth segments include antibody therapeutics, cell and gene therapies (CGT), mRNA vaccines, and digital therapeutics (DTx).

Structural Limitations of Traditional Biotech VC Investment

Despite the explosive growth potential of the biotech market, its early-stage investment landscape remains extremely closed and opaque.

• Information Asymmetry: Access to information on early-stage technologies is concentrated among a small number of scientists, VC analysts, and industry insiders. The general public and individual investors critically lack the information and expertise required to assess the viability of promising technologies.

• High Minimum Investment Amounts: Traditional VC funds demand a high Minimum Subscription Amount, often ranging from hundreds of thousands to millions of dollars, effectively creating an exclusive "league of their own" accessible only to high-net-worth individuals and institutional investors.

• Long-Term Illiquidity and Extended Lock-up Periods: Investments in early-stage biotech companies require a long-term horizon, typically averaging over 10 years, to see a return. Due to the nature of unlisted private stock, liquidation is nearly impossible before a major event like an M&A or IPO. This severe lack of liquidity is a significant deterrent to investment.

• High Management Fees: Traditional VCs often adhere to the "2 and 20" fee structure, collecting 2% of assets under management as an annual management fee and 20% of the profits as a performance fee. This model significantly erodes the actual returns for investors.

---

The Rise of a New Alternative: The Convergence of DeSci, RWA, and ESG Trends

The EXOT platform is born at the intersection of three massive megatrends that are currently shaping the financial and technological markets in 2025. The convergence of these three trends provides a powerful and differentiated market opportunity.

Decentralized Science (DeSci): The Democratization of Scientific Research

Decentralized Science (DeSci) is a movement that utilizes blockchain technology to innovate the funding, collaboration, and data-sharing methods of scientific research. It enhances transparency and opens new possibilities for anyone worldwide to contribute to research funding and share in its successes. However, "DeSci 1.0" models have shown limitations in raising the billion-dollar-scale capital required for new drug development and have faced challenges with governance inefficiencies by non-expert majorities. EXOT aims to overcome these limitations and lead the commercial maturation of DeSci.

Real-World Asset (RWA) Tokenization: The Emergence of a New Financial Infrastructure

Real-World Asset (RWA) tokenization is the technology of converting tangible, real-world assets like real estate and bonds into digital tokens on a blockchain. By 2025, driven by the participation of major financial institutions like BlackRock, the RWA market has matured into a robust financial infrastructure, surpassing $24 billion and projected to reach $50 billion by year's end. We leverage this mature RWA infrastructure to pioneer a new path—tokenizing and providing liquidity for the previously inaccessible real-world equity of unlisted private biotech companies.

ESG Investing: The Flow of Sustainable Capital

Environmental, Social, and Governance (ESG) investing has become the new standard in financial markets, with global investment volumes exceeding $50 trillion in 2025. The healthcare sector, in particular, aligns perfectly with the core ESG tenet of "Social Impact," making it a highly preferred sector for ESG investors. The EXOT Protocol's "Impact-Alpha Flywheel" model is structured to maximize financial returns by generating social impact through the treatment of intractable diseases, giving it a strong advantage in attracting large-scale, ESG-focused capital.

By capturing this historic moment where these three trends converge, EXOT aims to move beyond being a simple DeSci project. We seek to create a new asset class—"tokenized venture philanthropy"—and establish a first-mover advantage in an uncontested market space estimated to be worth $370 billion annually.